Clinical Trials · NCT02369796
A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Takeda
- Enrollment
- 15
- Start date
- Feb 2015
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Once Weekly Dosing Groups